CJC-1295 DAC and Tesamorelin structural differences

The comparison starts with the GHRH backbone

<a href="/product/cp-010">CP-010 CJC-1295 No-DAC</a>, <a href="/product/cp-011">CP-011 CJC-1295 DAC</a>, and <a href="/product/cp-018">CP-018 Tesamorelin</a> all belong in the growth hormone-releasing hormone analogue space. The structural comparison should start with the peptide backbone, not with commercial shorthand. CP-010 is cataloged at 3367.9 Da as a modified GHRH fragment 1-29 reference peptide. CP-011 is cataloged at 3647.9 Da as an albumin-binding GHRH analogue lyophilizate. CP-018 is cataloged at 5135.9 Da as a stabilised GHRH analogue reference standard.

For in-vitro research, the useful question is how the analogues differ as reference standards: chain length, terminal chemistry, modification state, albumin-binding appendage, and HPLC-MS verified identity. The article should avoid the full expanded phrase behind DAC because the site compliance rules block that wording. It can use DAC as a catalog term and define it as the albumin-binding appendage used in the CP-011 product line.

CJC-1295 No-DAC: a shorter modified GHRH fragment

The No-DAC form is the simpler reference object. Its release file should confirm the modified GRF(1-29) scaffold, the catalog mass, reversed-phase purity, and water and solvent lines. Because the backbone is close to Sermorelin-class GHRH fragments, <a href="/product/cp-017">CP-017 Sermorelin</a> is a useful adjacent link. It should be an UPDATE entry, not a primary target, unless the site team wants to strengthen the whole GHRH cluster.

A reader comparing CP-010 with CP-017 should focus on sequence substitutions and mass rather than family naming. The article can point to the <a href="/research-guide/ghrelin-mimetic-reference-standards">ghrelin mimetics</a> guide as the receptor-adjacent counterpart: CJC and Tesamorelin work through the GHRH receptor frame, while Ipamorelin, Hexarelin, and MK-677 belong to the ghrelin-receptor frame.

CJC-1295 DAC: appendage chemistry and mass shift

The DAC form adds the albumin-binding appendage and therefore has a different identity file. That modification changes molecular weight, chromatographic behaviour, and the impurity search. A release method should distinguish the intended appendage-bearing species from the unmodified backbone, incomplete coupling products, and hydrolysis-related variants. The 280 Da catalog difference between CP-010 and CP-011 is the first practical receiving check, but the chromatogram and MS trace need to carry the proof.

The article should say this plainly: CP-011 is not merely a longer-lasting label variant; it is a distinct modified reference standard with a different COA question. The buyer needs to confirm the appendage state. The product page can stay concise, but the research guide should show what an analytical reviewer is trying to prove when reading the lot record.

Tesamorelin: longer GHRH analogue, different mass window

Tesamorelin sits apart by mass and sequence length. At 5135.9 Da in the verified catalog, CP-018 requires a mass window and chromatographic method suitable for a larger peptide. Longer analogues can show broader peaks, more deletion-sequence possibilities, and stronger dependence on gradient design. A COA should make the method reproducible enough that a receiving lab can compare future lots against the same analytical frame.

This is where the article can help procurement officers: CP-010, CP-011, and CP-018 should not be compared with a one-line purity number. They should be compared through scaffold, mass, appendage or terminal state, method, lot number, and storage condition. That keeps the article technical and avoids unsupported equivalence language.

Method lines to inspect before accepting a lot

For all three SKUs, HPLC-MS verified identity is necessary. Reversed-phase HPLC should report the main peak with method context, including column chemistry, gradient, wavelength, and integration threshold. Karl Fischer water content matters for vial mass accounting. GC headspace residual-solvent screening matters because synthesis and purification solvents can persist at trace levels. These terms should link into the glossary so a procurement reader can understand the COA without leaving the research guide.

The Canada Peptides voice should be calm and specific: Toronto supplier, research reference standard, HPLC-MS verified, for in-vitro research use only and not for human or veterinary use. There is no need to describe biological outcomes. The structural facts carry the page: modified GHRH fragment, albumin-binding appendage, larger Tesamorelin analogue, and lot-specific analytical evidence.

Cross-linking the growth cluster

The primary reverse-index ADD entries should be CP-010, CP-011, and CP-018. CP-017 can be an UPDATE entry because Sermorelin is the natural GHRH comparator. The article should also link to <a href="/research-guide/ghrelin-mimetic-reference-standards">Ghrelin mimetics: Ipamorelin, MK-677, and Hexarelin</a> and <a href="/research-guide/reading-a-coa">How to read a Certificate of Analysis</a>. Together, those links create a clean separation between GHRH analogues and GHSR-1a ligands.

The glossary anchors should include <a href="/glossary/hplc-ms">HPLC-MS</a>, <a href="/glossary/molecular-weight">molecular weight</a>, <a href="/glossary/c-terminal">C-terminal</a>, and <a href="/glossary/counter-ion">counter-ion</a>. Readers who arrive through a long-tail CJC query can move from the article to the relevant PDP, to the COA vocabulary, and to adjacent growth-family content.

Summary

CJC-1295 No-DAC, CJC-1295 DAC, and Tesamorelin are best compared as GHRH-analogue reference standards. CP-010 is the shorter modified fragment, CP-011 adds an albumin-binding appendage, and CP-018 occupies a larger mass window. The COA should prove the assigned scaffold rather than rely on shorthand naming.

The article closes the orphaned-PDP gap for CP-010, CP-011, and CP-018, while giving CP-017 a clean adjacent update link. It stays structural, method-led, and compatible with the site compliance rules.

Release-file review checklist

For release-file review, keep the chemistry anchored to the verified SKU list: CP-010, CP-011, CP-018, CP-017. Confirm sequence or scaffold, molecular weight, HPLC-MS verified identity, counter-ion or modification state, water content, and residual-solvent method before copying the article into a production CMS. Canada Peptides should keep each inline product reference tied to the lower-case PDP route and should keep the article language limited to research reference standard selection, analytical characterisation, and procurement traceability. If a future catalog update changes a molecular weight, adds a salt form, or introduces a new related product, revise the cross-links and the patch file before publication rather than editing the claim in isolation.

Human review should confirm whether production wants DAC expanded anywhere. This draft intentionally avoids the blocked word in the expansion and uses appendage chemistry instead.

Procurement traceability notes

A procurement reader should be able to move from this article to a PDP, from the PDP to a lot COA, and from the COA to a reproducible method record without guessing. That means names, SKU codes, molecular weights, and analytical terms must stay consistent across the article body, glossary, and reverse-index patch. The article should therefore be handled as a controlled content asset: update the reviewed date, check the DOI links, rerun the banned-phrase scan, and confirm the article still links to at least three product pages and two research-guide resources before publication.

Publication integration notes

This article should be the canonical GHRH-analogue page for the growth cluster. It needs to sit near, but not merge with, the ghrelin-mimetic article. The distinction is simple enough for a procurement officer to use: CP-010, CP-011, CP-017, and CP-018 belong to the GHRH analogue frame; CP-012, CP-013, CP-014, CP-015, and CP-016 belong to the GHSR-1a frame. Keeping those pages separate creates cleaner internal linking and reduces the chance that a buyer compares unrelated scaffold classes by one purity number.

The compliance risk is the DAC expansion. The site rules block one word that appears in the conventional expansion, so the article uses DAC as a catalog term and explains it as an albumin-binding appendage. That is enough for structural understanding. If production needs a formal abbreviation note, it should be reviewed by the compliance owner first. The article should keep its method vocabulary tight: scaffold, appendage, mass, chromatogram, HPLC-MS identity, water content, residual solvent, lot number, and storage condition.

CMS acceptance notes

Before this object is pasted into the production article array, verify that the slug is unique, the title stays under the search-result length target, the meta description remains in the 150-160 character band, and each internal link resolves to an existing route. Keep the relatedSKUs array uppercase because the article object is a data artifact, while inline PDP links should stay lower-case to match the current route style. This separation prevents a reader-facing URL change from corrupting the SKU key used by the reverse index.

The publication checklist should be mechanical. Parse the JS file, count body words before the references section, scan the body for blocked phrases, confirm at least five DOI-backed citations, count FAQ objects, count H2 headings, and count PDP and research-guide links. Then compare the article's SKU list with pdp_to_article_map_v3_patch.json. If the content and patch disagree, fix both in the same edit. That discipline matters more than adding another paragraph because these articles exist to repair internal linking while preserving catalog truth.

References

1. Mayo, K. E. (1992). Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology, 6(10), 1734–1744. DOI: 10.1210/me.6.10.1734 2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. The Journal of Clinical Endocrinology &Amp; Metabolism, 91(3), 799–805. DOI: 10.1210/jc.2005-1536 3. Ionescu, M., & Frohman, L. A. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology &Amp; Metabolism, 91(12), 4792–4797. DOI: 10.1210/jc.2006-1702 4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.-P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290–E1294. DOI: 10.1152/ajpendo.00201.2006 5. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989). Electrospray Ionization for Mass Spectrometry of Large Biomolecules. Science, 246(4926), 64–71. DOI: 10.1126/science.2675315

Frequently asked questions

References

1. Mayo, K. E. (1992). Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molecular Endocrinology, 6(10), 1734–1744. · link
2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.-P., & Frohman, L. A. (2006). Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. The Journal of Clinical Endocrinology &Amp; Metabolism, 91(3), 799–805. · link
3. Ionescu, M., & Frohman, L. A. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology &Amp; Metabolism, 91(12), 4792–4797. · link
4. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J.-P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290–E1294. · link
5. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989). Electrospray Ionization for Mass Spectrometry of Large Biomolecules. Science, 246(4926), 64–71. · link

References

1. Ionescu M., Frohman L. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology &amp; Metabolism. · DOI
2. Henninge J., Pepaj M., Hullstein I. et al. (2010). Identification of CJC‐1295, a growth‐hormone‐releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. · DOI
3. Timms M., Ganio K., Forbes G. et al. (2018). An immuno polymerase chain reaction screen for the detection of CJC‐1295 and other growth‐hormone‐releasing hormone analogs in equine plasma. Drug Testing and Analysis. · DOI
4. Howard A., Feighner S., Cully D. et al. (1996). A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release. Science. · DOI
5. Kojima M., Hosoda H., Date Y. et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. · DOI
6. Merrifield R. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society. · DOI
7. FIELDS G., NOBLE R. (1990). Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research. · DOI
8. Whitelegge J. (n.d.). HPLC and Mass Spectrometry of Intrinsic Membrane Proteins. HPLC of Peptides and Proteins. · DOI